A South Korean biotech company has filed an appeal with the Federal Court after an Ashurst partner succeeded in opposing the company’s proposed patent for a genome editing technology.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au